H. Lundbeck, A/S

Cipralex approved for the treatment of generalized anxiety disorder in the EU

Published in Law and Health Weekly, October 29th, 2005

The European health authorities have approved Cipralex for the treatment of generalized anxiety disorder (GAD), according to Danish pharmaceutical company H. Lundbeck, A/S.

The approval is based on seven clinical studies involving more than 1600 patients. The studies all demonstrate that Cipralex is an effective and well-tolerated drug for the treatment of GAD.

It is estimated more than half of the patients suffering from GAD also suffer from another psychiatric disorder, primarily depression. In Europe, Cipralex has, in addition to GAD, also been approved for the treatment of depression, social disorders, and panic disorders, which means the drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-10-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry